SCO-120 is a novel, orally-active, Selective Estrogen Receptor Degrader (SERD) targeting both wild type and mutant forms of ER.

Anti-estrogen therapy is the mainstay of treatment for women with breast cancer whose tumors express ERα and the degradation of ERα is deemed a superior therapeutic approach in the treatment of ER +ve breast cancer.

Also, it is known that approximately 20-50% of patients with metastatic breast cancer develop resistance to antiestrogen therapies due to the emergence of mutations in the ERα. Given the current treatment options, there is an unmet need for an orally bioavailable SERD that can target both wild type and mutant forms of ER.

SCO-120 has demonstrated potent in-vitro SERD activity in breast cancer cells expressing ERα wild type (WT) and its mutants. Along with this it has also shown robust tumor growth inhibition of Wild Type (WT) as well as Y537S and D538G xenografts.

Furthermore, SCO-120 has been studied in combination with a CDK 4/6 inhibitor and the effects have shown to be further enhanced in these pre-clinical combination studies.
 

SPARC has initiated a Phase 1 study in the US to assess the PK and Safety of SCO-120 in healthy volunteers.